Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cisplatin,2-Hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Intensity Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Intensity Therapeutics, Sakk Ink Agreement for Phase 2 Trial in Early-Stage Cancer
Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 13, 2024
Lead Product(s) : Cisplatin,2-Hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Intensity Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Oasmia Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK
Details : SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Oasmia Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
